These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 39330867)

  • 1. The Role of the N-Terminal Domain of Thrombomodulin and the Potential of Recombinant Human Thrombomodulin as a Therapeutic Intervention for Shiga Toxin-Induced Hemolytic-Uremic Syndrome.
    Kröller S; Schober J; Krieg N; Dennhardt S; Pirschel W; Kiehntopf M; Conway EM; Coldewey SM
    Toxins (Basel); 2024 Sep; 16(9):. PubMed ID: 39330867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of recombinant human soluble thrombomodulin for the treatment of shiga toxin-associated hemolytic uremic syndrome model mice.
    Suyama K; Kawasaki Y; Miyazaki K; Kanno S; Ono A; Ohara S; Sato M; Hosoya M
    Nephrol Dial Transplant; 2015 Jun; 30(6):969-77. PubMed ID: 25694534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of the lectin-like domain of thrombomodulin worsens Shiga toxin-associated hemolytic uremic syndrome in mice.
    Zoja C; Locatelli M; Pagani C; Corna D; Zanchi C; Isermann B; Remuzzi G; Conway EM; Noris M
    J Immunol; 2012 Oct; 189(7):3661-8. PubMed ID: 22942429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic use of a receptor mimic probiotic reduces intestinal Shiga toxin levels in a piglet model of hemolytic uremic syndrome.
    Hostetter SJ; Helgerson AF; Paton JC; Paton AW; Cornick NA
    BMC Res Notes; 2014 Jun; 7():331. PubMed ID: 24890228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis.
    Morigi M; Galbusera M; Gastoldi S; Locatelli M; Buelli S; Pezzotta A; Pagani C; Noris M; Gobbi M; Stravalaci M; Rottoli D; Tedesco F; Remuzzi G; Zoja C
    J Immunol; 2011 Jul; 187(1):172-80. PubMed ID: 21642543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of recombinant human soluble thrombomodulin for childhood hemolytic uremic syndrome.
    Kawasaki Y; Suyama K; Ono A; Oikawa T; Ohara S; Suzuki Y; Sakai N; Hosoya M
    Pediatr Int; 2013 Oct; 55(5):e139-42. PubMed ID: 24134770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the innate repair receptor axis
    Dennhardt S; Pirschel W; Wissuwa B; Imhof D; Daniel C; Kielstein JT; Hennig-Pauka I; Amann K; Gunzer F; Coldewey SM
    Front Immunol; 2022; 13():1010882. PubMed ID: 36211426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Genomics of Shiga Toxin-Producing Escherichia coli Strains Isolated from Pediatric Patients with and without Hemolytic Uremic Syndrome from 2000 to 2016 in Finland.
    Bai X; Ylinen E; Zhang J; Salmenlinna S; Halkilahti J; Saxen H; Narayanan A; Jahnukainen T; Matussek A
    Microbiol Spectr; 2022 Aug; 10(4):e0066022. PubMed ID: 35730965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shiga toxin targets the podocyte causing hemolytic uremic syndrome through endothelial complement activation.
    Bowen EE; Hurcombe JA; Barrington F; Keir LS; Farmer LK; Wherlock MD; Ortiz-Sandoval CG; Bruno V; Bohorquez-Hernandez A; Diatlov D; Rostam-Shirazi N; Wells S; Stewart M; Teboul L; Lay AC; Butler MJ; Pope RJP; Larkai EMS; Morgan BP; Moppett J; Satchell SC; Welsh GI; Walker PD; Licht C; Saleem MA; Coward RJM
    Med; 2023 Nov; 4(11):761-777.e8. PubMed ID: 37863058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experimental In Vivo Models of Bacterial Shiga Toxin-Associated Hemolytic Uremic Syndrome.
    Jeong YJ; Park SK; Yoon SJ; Park YJ; Lee MS
    J Microbiol Biotechnol; 2018 Sep; 28(9):1413-1425. PubMed ID: 29926707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemolytic uremic syndrome due to Shiga toxin-producing Escherichia coli infection.
    Bruyand M; Mariani-Kurkdjian P; Gouali M; de Valk H; King LA; Le Hello S; Bonacorsi S; Loirat C
    Med Mal Infect; 2018 May; 48(3):167-174. PubMed ID: 29054297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary Human Derived Blood Outgrowth Endothelial Cells: An Appropriate In Vitro Model to Study Shiga Toxin Mediated Damage of Endothelial Cells.
    Feitz WJC; van de Kar NCAJ; Cheong I; van der Velden TJAM; Ortiz-Sandoval CG; Orth-Höller D; van den Heuvel LPJW; Licht C
    Toxins (Basel); 2020 Jul; 12(8):. PubMed ID: 32751286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shiga toxin triggers endothelial and podocyte injury: the role of complement activation.
    Zoja C; Buelli S; Morigi M
    Pediatr Nephrol; 2019 Mar; 34(3):379-388. PubMed ID: 29214442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenesis of Shiga toxin-induced hemolytic uremic syndrome.
    Ray PE; Liu XH
    Pediatr Nephrol; 2001 Oct; 16(10):823-39. PubMed ID: 11605791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenic role of inflammatory response during Shiga toxin-associated hemolytic uremic syndrome (HUS).
    Exeni RA; Fernandez-Brando RJ; Santiago AP; Fiorentino GA; Exeni AM; Ramos MV; Palermo MS
    Pediatr Nephrol; 2018 Nov; 33(11):2057-2071. PubMed ID: 29372302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extrarenal manifestations of the hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC HUS).
    Khalid M; Andreoli S
    Pediatr Nephrol; 2019 Dec; 34(12):2495-2507. PubMed ID: 30382336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New insights into Shiga toxin-mediated endothelial dysfunction in hemolytic uremic syndrome.
    Petruzziello-Pellegrini TN; Moslemi-Naeini M; Marsden PA
    Virulence; 2013 Aug; 4(6):556-63. PubMed ID: 23955166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Commentary: Campylobacter and Hemolytic Uremic Syndrome.
    Smith JL; Gunther NW
    Foodborne Pathog Dis; 2019 Feb; 16(2):90-93. PubMed ID: 30307748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular impairment in Shiga-toxin-2-induced experimental hemolytic-uremic syndrome: a pilot study.
    Neu C; Wissuwa B; Thiemermann C; Coldewey SM
    Front Immunol; 2023; 14():1252818. PubMed ID: 37809105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody response to lipopolysaccharides and recombinant proteins of Shiga toxin (STX)-producing Escherichia coli (STEC) in children with haemolytic uraemic syndrome in Poland.
    Rastawicki W; Śmietańska K; Rokosz-Chudziak N; Wołkowicz T
    Lett Appl Microbiol; 2020 Jun; 70(6):440-446. PubMed ID: 32270510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.